Tonix Pharmaceuticals Holding Corp. (TNXP)
13.14
-0.23
(-1.72%)
USD |
NASDAQ |
Sep 04, 16:00
13.33
+0.19
(+1.45%)
After-Hours: 20:00
Tonix Pharmaceuticals Research and Development Expense (Quarterly) : 19.42M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 19.42M |
| March 31, 2026 | 18.21M |
| December 31, 2025 | 16.94M |
| September 30, 2025 | 9.289M |
| June 30, 2025 | 10.82M |
| March 31, 2025 | 7.436M |
| December 31, 2024 | 8.297M |
| September 30, 2024 | 9.114M |
| June 30, 2024 | 9.698M |
| March 31, 2024 | 12.86M |
| December 31, 2023 | 17.12M |
| September 30, 2023 | 21.05M |
| June 30, 2023 | 21.98M |
| March 31, 2023 | 26.51M |
| December 31, 2022 | 24.67M |
| September 30, 2022 | 22.20M |
| June 30, 2022 | 16.58M |
| March 31, 2022 | 18.42M |
| December 31, 2021 | 22.30M |
| September 30, 2021 | 13.08M |
| June 30, 2021 | 18.13M |
| March 31, 2021 | 15.33M |
| December 31, 2020 | 12.10M |
| September 30, 2020 | 8.813M |
| June 30, 2020 | 10.57M |
| Date | Value |
|---|---|
| March 31, 2020 | 4.676M |
| December 31, 2019 | 5.69M |
| September 30, 2019 | 5.052M |
| June 30, 2019 | 3.554M |
| March 31, 2019 | 3.896M |
| December 31, 2018 | 5.057M |
| September 30, 2018 | 3.264M |
| June 30, 2018 | 4.067M |
| March 31, 2018 | 5.17M |
| December 31, 2017 | 3.634M |
| September 30, 2017 | 3.908M |
| June 30, 2017 | 2.806M |
| March 31, 2017 | 2.994M |
| December 31, 2016 | 4.88M |
| September 30, 2016 | 5.466M |
| June 30, 2016 | 7.516M |
| March 31, 2016 | 10.67M |
| December 31, 2015 | 9.49M |
| September 30, 2015 | 10.31M |
| June 30, 2015 | 8.871M |
| March 31, 2015 | 6.829M |
| December 31, 2014 | 5.775M |
| September 30, 2014 | 5.217M |
| June 30, 2014 | 4.075M |
| March 31, 2014 | 3.55M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Exelixis, Inc. | 211.99M |
| Inovio Pharmaceuticals, Inc. | 10.50M |
| Heron Therapeutics, Inc. | 2.702M |
| ACADIA Pharmaceuticals, Inc. | 81.56M |
| Alnylam Pharmaceuticals, Inc. | 413.13M |